Biotech Values

[DewDiligence]

AMGN—Repatha shows statsig reduction in CV risk (and non-inferior cognitive function relative to placebo):

http://finance.yahoo.com/news/amgen-announces-repatha-evolocumab-significantly-210000355.html

Amgen (AMGN) today announced that the FOURIER trial evaluating whether Repatha (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke). No new safety issues were observed.

The EBBINGHAUS cognitive function trial conducted in FOURIER patients also achieved its primary endpoint, demonstrating that Repatha was non-inferior to placebo for the effect on cognitive function.

This is the first PCSK9 CVOT to report data. Full data from both trials mentioned above will be presented at ACC on 3/17/17.